Navid Sobhani, Ph.D
Navid Sobhani, Ph.D
- Postdoctoral Fellow
Medicine - Epidemiology & Population Science
Baylor College of Medicine
- Ph.D Degree
Department of Medical, Surgical and Health Sciences
University of Trieste
Trieste, Friuli Venezia Giulia Italy
Investigation of the prognostic and drug-predictive role of the immune system in solid tumors.
- Associate Researcher
Department of Cancer Stem Cells
Istitute of National Health
Rome, Lazio Italy
Biological evaluation of the efficacy of peptide-drug conjugates drug delivery to cancer cells and cancer stem cells.
- Associate Researcher
Department of Chemical Engineering and Biotechnology
University of Cambridge
Cambridge, Cambridgeshire United Kingdom
• Developed novel methods for blood based biomarker discovery in Schizophrenia using LC-MSe and MRM mass spectrometry. • Implemented an efficient method for exosome isolation from serum for proteomic profiling.
- MSc Thesis
Institute FIRC of Molecular Oncology
Mlilan, Lombardia Italy
• Explored the opposing role of TALE family transcription factors Meis 1 and Prep 1 proteins in breast cancer pathogenesis, through infection of MCF10A with vectors altering expression level of these two proteins.
- One Baylor Plaza (Office)
Houston, TX 77030
- PhD from University of Trieste
- 03/2020 - Trieste, Italy
- MS from University of Cambridge
- 12/2014 - Cambridge, United Kingdom
- MSc from University of Aberdeen
- 07/2013 - Aberdeen, Aberdeenshire United Kingdom
- "PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.." EBioMedicine.2017/August;22:18-19. Pubmed PMID: 28688823
- "Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: a literature based meta-analysis of randomized trials.." Annals of Oncology.2016/November;:
- "The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.." J Cell Biochem.2018;119:4287–4292.
- "Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study." Breast Cancer Res Treat.2020/August7;: Pubmed PMID: 32770287
- "CTLA-4 in Regulatory T Cells for Cancer Immunotherapy." Cancers. 2021 March 22; 13 (6): 1440.
- "Cancer/Testis Antigens: from Serology to mRNA Cancer Vaccine." Seminars in Cancer Biology. 2021 April 25; :
- "Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer." Cells. 2021 February 1; : Pubmed PMID: 33535617
- "Tumour Infiltrating Lymphocytes and Immune-Related Genes as Predictors of Outcome in Pancreatic Adenocarcinoma." PLoS One. 2019 14 (8): Pubmed PMID: 31381571
- "Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma." Mol Biol Rep. 2019 March 6; 46 : 2713–2720. Pubmed PMID: 30840203
- Navid Sobhani, Bruna Scaggiante, Rachel Morris, Dafei Chai, Martina Catalano, Dana Rae Tardiel-Cyril, Praveen Neeli, Giandomenico Roviello, Giuseppina Mondani, Yong Li "Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials." Cancer Treatment Review. 2022 June 22; 109 : 102429. Pubmed PMID: 35759856
- "IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy." Cancers. 2022 June 9; 14 (12): 2861. Pubmed PMID: 35740527
- "Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer." Cancers. 2020 November 10; 12 (11): 3314.
- AI-Assisted Therapeutic CTLA-4 Strategies
- Baylor College of Medicine
- Using Artificial Intelligence (AI) I would like to have millions of possible targeting compounds screened to find the best cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors to elicit an immune-response to solid tumors. CTLA-4 plays an important role in hindering the anticancer immunity and novel solutions to therapeutically intervene could prove of a great benefit in advanced tumors. After detecting the most efficient leads I would like to investigate their mode of action in cancer cells. In an area where FDA-approved immunotherapies targeting CTLA-4 and PD-1/PD-L1 elicit strong antitumor T-cell responses in various types of cancers, there is still a lack to completely understand the role of T-cells in cancer immunology. The area excites my interest to pioneer new structures that could powerfully elicit the immune system while lowering adverse events. In this context I am looking at the two roles of CTLA-4: from one side antagonist can be used to boost the immune system against cancer; on the other side agonist could be used to block the immune reactions in the context of auto-immune diseases and more spectacularly it would be great to have drugs efficient against SARS and the current COVID-19.
- DNA Therapeutic Cancer Vaccine Delivery Against PD-1
- Baylor College of Medicine (05/2020 - present)
- As the field of vaccination has been tremendously growing culminating with FDA-approval of great RNA vaccines against COVID-19, I would like bridge this field with the production of RNA- or even DNA-based cancer vaccines. Ferritin nanoparticle is a self-assembling multimeric vaccine platform that has been used previously for displaying antigens like Influenza and Epstein-Barr virus. Currently, I am looking into the generation of DNA vaccines against PD-1 in ferritin nanoparticle, possibly improving current methods of Plasmid delivery in-vivo through different techniques.
- NEW AND MORE 'POWERFUL MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF neuroendocrine tumors (NETs) E OF STEM CELLS OF NETs
- Product Patent (Approved)
Log In to edit your profile